NeoGenomics Launches RaDaR ST for Molecular Residual Disease Detection in Solid Tumors (ir.neogenomics.com)

• RaDaR ST ctDNA assay launched for MRD detection in solid tumors
• Tumor-informed panels track up to 48 variants; LOD95 of 11 ppm
• Medicare approved for initial indications; two more submitted
• MRD market estimated at >$20B, 30% CAGR, <10% penetrated

"NeoGenomics launched RaDaR ST, a ctDNA assay for molecular residual disease (MRD) in solid tumors. It uses patient-specific, tumor-informed panels tracking up to 48 variants with a limit of detection of 11 ppm (LOD95). Medicare approved for initial indications; two more under review. The MRD market is estimated at over $20 billion, growing 30% annually and less than 10% penetrated."